Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study

Neurology

Volumn 59, Issue 8, 2002, Pages 1210-1217

  Sandrini, G ^a   Farkkila M ^b   Burgess, G ^c,d   Forster, E ^d   Haughie, S ^d  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c II Military Hospital   (South Africa)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ELETRIPTAN; PLACEBO; SUMATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PATIENT ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SWEATING; SYMPTOMATOLOGY; VERTIGO;

EID: 0037159234     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.8.1210     Document Type: Article

References (20)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-657.
2. US Bureau of the Census. Resident Population Estimates of the United States by Age and Sex: April 1, 1990 to July 1, 1999 With Short-Term Projection to November 1, 2000. Washington, DC: US Bureau of the Census, 1999.
3. Dahlöf C, Linde M. One-year prevalence of migraine in Sweden: a population based study in adults. Cephalalgia 2001;21:664-671.
4. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996;47:52-59.
5. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13:667-676.
6. Hopkins A. The epidemiology of headache and migraine, and its meaning for neurological services. Schweiz Med Wochenschr 1996;126:128-135.
7. 1D receptors. Eur J Pharmacol 1999;368:259-268.
8. 1B/1D receptor agonist. Eur J Pharmacol 2000;398:73-81.
9. HT1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002;42:528-539.
10. Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002;42:520-527.
11. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000;54:156-163.
12. Diener H-C, Reches A, Jansen JP, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability, and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002;47:99-107.
13. Stark R, Dahlöf C, Haughie S, Hettiarachchi J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a Phase III, multicentred, placebo-controlled study across three attacks. Cephalalgia 2002;22:23-32.
14. Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg, and 80 mg in Japanese migraineurs. Cephalalgia. In press.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
16. Fuseau E, Petricoul O, Sabin A, et al. Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clin Ther 2001;23:242-251.
17. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991;31:295-299.
18. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-786.
19. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-1675.
20. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998;38:737-747.